Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Investigators patent novel technique for detecting carcinomas in oral mucosa

Investigators patent novel technique for detecting carcinomas in oral mucosa

Breast surgery for low-grade ductal carcinoma in-situ may not change patients' survival rate

Breast surgery for low-grade ductal carcinoma in-situ may not change patients' survival rate

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

New treatment option for postmenopausal women with non-invasive breast cancer

New treatment option for postmenopausal women with non-invasive breast cancer

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

NSCLC treatment market forecast to reach $7.9 billion by 2020

NSCLC treatment market forecast to reach $7.9 billion by 2020

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.